As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Lyme disease is the most common tick-borne infectious disease in the United States. Named for the Connecticut town where it was first reported in the 1970s, Lyme is prevalent in the northeast and ...

Pfizer (NYSE:PFE) used its 2026 annual meeting of shareholders to highlight recent operational performance, outline strategic ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Anchored by TV spots and sports media placements, the Every Inch Matters campaign positions the projected number one overall ...

BridgeBio rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's Vyndamax ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...